Literature DB >> 17023833

Antitumor activity of nifurtimox observed in a patient with neuroblastoma.

Giselle L Saulnier Sholler1, Satyan Kalkunte, Carla Greenlaw, Kathleen McCarten, Edwin Forman.   

Abstract

BACKGROUND: Chemotherapy-resistant neuroblastoma is a difficult disease to treat with poor survival. OBSERVATIONS: We treated a patient with neuroblastoma who had progressed on conventional chemotherapy. This 5-year-old girl with chemotherapy-resistant neuroblastoma developed Chagas disease at the start of salvage chemotherapy for which she was also started on nifurtimox. The neuroblastoma response to these treatments resulted in clinical remission. In vitro, treatment of a neuroblastoma cell line with nifurtimox resulted in decreased cell viability whereas no effect was seen on an endothelial cell line.
CONCLUSIONS: Nifurtimox shows promise as a potential new treatment for neuroblastoma and warrants further testing.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17023833     DOI： 10.1097/01.mph.0000212994.56812.f2

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


  13 in total

1.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.

Authors:  Chris Bot; Belinda S Hall; Noosheen Bashir; Martin C Taylor; Nuala A Helsby; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

3.  A comparison of toxicity and toxicokinetics in rats and dogs following twenty-eight-day, repeat-dose oral administration of nifurtimox.

Authors:  Ye Li; Tian-Tian Liu; Hong-Tao Jin; Piao-Piao Zhang; Dan Qin; Qian-Qian Zhang; Wen-Tao Wu; Cui-Ping Yang; Ai-Ping Wang
Journal:  Toxicol Res (Camb)       Date:  2017-05-17       Impact factor: 3.524

4.  The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions.

Authors:  Quhuan Li; Qun Lin; Hoon Kim; Zhong Yun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

5.  Evaluating 5-nitrofurans as trypanocidal agents.

Authors:  Christopher Bot; Belinda S Hall; Guzmán Alvarez; Rossanna Di Maio; Mercedes González; Hugo Cerecetto; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

6.  A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.

Authors:  Rakesh K Singh; Thilo S Lange; Kyu Kwang Kim; Laurent Brard
Journal:  Invest New Drugs       Date:  2009-10-29       Impact factor: 3.850

7.  Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo.

Authors:  Giselle L Saulnier Sholler; Laurent Brard; Jennifer A Straub; Lee Dorf; Sharon Illeyne; Karen Koto; Satyan Kalkunte; Marcus Bosenberg; Taka Ashikaga; Rae Nishi
Journal:  J Pediatr Hematol Oncol       Date:  2009-03       Impact factor: 1.289

8.  An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.

Authors:  Andrew A Voak; Vithurshaa Gobalakrishnapillai; Karin Seifert; Edina Balczo; Longqin Hu; Belinda S Hall; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

9.  Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.

Authors:  Belinda S Hall; Christopher Bot; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

10.  Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience.

Authors:  Emmad E Habib; Amr T El-Kashef; Ezzat S Fahmy
Journal:  Oncol Rev       Date:  2012-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.